Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (comparator and an oral fumarate in relapsing-remitting multiple sclerosis) study

被引：0

作者：

Hutchinson, M. ^{[1
]}

Fox, R. J. ^{[2
]}

Miller, D. ^{[3
]}

Phillips, J. T. ^{[4
]}

Kita, M. ^{[5
]}

Havrdova, E. ^{[6
]}

O'Gorman, J. ^{[7
]}

Yang, M. ^{[7
]}

Novas, M. ^{[7
]}

Viglietta, V. ^{[7
]}

Dawson, K. T. ^{[7
]}

机构：

[1] St Vincents Univ Hosp, Dublin 4, Ireland

[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA

[3] UCL, Inst Neurol, NMR Res Unit, London, England

[4] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA

[5] Virginia Mason Med Ctr, Seattle, WA 98101 USA

[6] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic

[7] Biogen Idec Inc, Weston, MA USA

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2012年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：355 / 355

页数：1

共 50 条

[1] Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study
Hutchinson, M.
Fox, R. J.
Miller, D.
Phillips, J. T.
Kita, M.
Havrdova, E.
Yang, M.
Zhang, R.
Novas, M.
Viglietta, V.
Dawson, K. T.
JOURNAL OF NEUROLOGY, 2012, 259 : S105 - S106
[2] Safety and tolerability of BG-12 in patients with relapsing-remitting multiple sclerosis: results from the phase 3 CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study
Havrdova, E.
Phillips, J. T.
Fox, R. J.
Miller, D.
Kita, M.
Hutchinson, M.
Raghupathi, K.
Yuan, H.
Novas, M.
Sweetser, M. T.
Viglietta, V.
Dawson, K. T.
JOURNAL OF NEUROLOGY, 2012, 259 : S105 - S105
[3] Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM
Havrdova, Eva
Hutchinson, Michael
Kurukulasuriya, Nuwan C.
Raghupathi, Kartik
Sweetser, Marianne T.
Dawson, Katherine T.
Gold, Ralf
EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (15) : 2145 - 2156
[4] Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study
Bar-Or, Amit
Gold, Ralf
Kappos, Ludwig
Arnold, Douglas
Giovannoni, Gavin
Selmaj, Krzysztof
O'Gorman, John
Stephan, Monica
Dawson, Katherine
NEUROLOGY, 2012, 78
[5] Effects of BG-12 on quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study
Kita, M.
Fox, R. J.
Phillips, J. T.
Hutchinson, M.
Havrdova, E.
Sarda, S. P.
Kong, J.
Viglietta, V.
Sheikh, S. I.
Dawson, K. T.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 254 - 254
[6] Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study
Miller, D. H.
Hutchinson, M.
Fox, R. J.
Phillips, J. T.
Kita, M.
Havrdova, E.
O'Gorman, J.
Yang, M.
Viglietta, V.
Dawson, K. T.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 189 - 190
[7] Oral fumarate for relapsing-remitting multiple sclerosis
Sorensen, Per Soelberg
Sellebjerg, Finn
LANCET, 2008, 372 (9648): : 1447 - 1448
[8] Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from Two Phase 3 Studies (DEFINE and CONFIRM)
Hutchinson, M.
Bar-Or, A.
Fox, R. J.
Gold, R.
Giovannoni, G.
Kita, M.
O'Gorman, J.
Yang, M.
Sheikh, S. I.
Viglietta, V.
Dawson, K. T.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 682 - 683
[9] Advances in the management of relapsing-remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12)
Nielsen, A. Scott
DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2015, 5
[10] Efficacy and Safety of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis in the Phase 3 CONFIRM Study
Hutchinson, M.
Fox, R. J.
Phillips, J. T.
Miller, D. H.
Havrdova, E.
Kita, M.
Yang, M.
Zhang, R.
Novas, M.
Sweetser, M. T.
Viglietta, V.
Dawson, K. T.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 683 - 683

← 1 2 3 4 5 →